Skip to main content

Table 6 Comparison of CR/PR and SD/PD efficacy in different treatment groups

From: Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer

 

UX therapy

(n = 40)

Eri therapy

(n = 39)

P-value

CR/PR

8

9

0.739

SD/PD

32

30

  1. CR: complete response; PR: partial response; SD stable disease; PD: progressive disease
  2. UX (Utidelone plus Capecitabine); Eri(Eribulin)
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us